Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
NEJM Evidence|May 28, 2024
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure SyndromesTapan M Kadia, Meixian Huang, Naveen Pemmaraju, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
NEJM Evidence|May 28, 2024
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure SyndromesTapan M Kadia, Meixian Huang, Naveen Pemmaraju, et al.
Pageof 16